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Detection of antiplatelet antibody activity in patients with renal
cortical necrosis. Sera were collected from 14 patients with renal
cortical necrosis (RCN) and tested for lymphocytotoxic anti-
body, antiglomerular basement membrane antibody and anti-
platelet antibody. Three of 11 patients (27%) had at least one
lymphocytotoxic antibody, none had anti-GBM antibody, while
11 of 14 patients (79%) were found to have a serum factor which
released platelet factor III. Antiplatelet antibody activity was
found in 33% of sera from 23 patients with non-RCN renal
failure. It was of interest to note that the higher incidence of
antiplatelet antibody activity in RCN was accompanied by a
high incidence of early allograft faulure in 31 such patients re-
ceiving renal transplantation.
Detection d'une activité auticorps anti-plaguettes chez des
malades atteints de nécrose corticale du rein. Le serum de
14 malades atteints de necrose corticale rénale (RCN) a été
étudié pour rechercher des anticrops lymphocytotoxiques, anti-
membrane basale glomCrulaire (GBM) et antiplaquettes. Trois
malades sur 11 (27%) avaient au moms un anticorps lympho-
cytotoxique, aucun n'avait d'anticorps anti-GBM et 11 malades
sur 14 (74%) avaient un facteur serique qui libérait le facteur
plaquettaire III. Une activité anticorps anti-plaquettes a été
trouvée dans 33% des serums de 23 malades atteints d'insuffis-
ance rénale sans RCN. Ii est intéressant de remarquer que Ia
fréquence élevée d'activité anticorps anti-plaquettes dans RCN
est concomittante d'une frequence élevée de rejets précoces de
greffes chez 31 de ces malades soumis a une transplantation
rénale.
Renal cortical necrosis (RCN) is a pathological
lesion characterized by ischemic necrosis of varying
portions of renal cortex while sparing, in most cases,
the medulla and a thin subcapsular layer [1]. Clinically,
RCN is associated with abrupt onset of gross hema-
tuna, oliguria, anuria and subsequent uremia. Patients
having diffuse bilateral RCN invariably require repe-
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titive hemodialysis or peritoneal dialysis or trans-
plantation to sustain life; however, patients with less
extensive disease may survive without requiring such
support [2, 3].
Almost all cases of RCN occur in one of four clinical
settings: obstetrical accidents [4], septicemia, trau-
matic injury to the kidney or hyperacute renal allograft
rejection (allograft RCN) [5, 6]. The pathogenesis of
RCN, however, has been elucidated in only one form,
allograft RCN, where circulating antibodies against
the graft result in the renal lesion [6, 7]. The patho-
genesis of RCN in other forms remains less clear. It
has been suggested, for example, that following abrup-
tio placenta RCN occurs because of the sudden re-
lease of large amounts of placental thromboplastin-like
material [8]. In this paper we report investigation into
the incidence of cytotoxic antibody in forms of RCN
other than allograft RCN. Sera collected from patients
with RCN were tested for cytotoxic antibodies and,
since early or hyperacute rejection is associated with
circulating antibodies, the transplantation courses of
patients with RCN were reviewed to determine the in-
cidence of early graft failure.
Methods
Collection of sera from patients with RCN. Through
a letter sent to approximately 200 dialysis centers in
46 states, 15 cases of RCN were located. Frozen
serum samples from 14 of these patients were obtained.
Clinical data from these patients are presented in
Table 1.
Evaluation of sera from patients with RCN. Lympho-
cytotoxic antibodies in the sera of patients with
RCN were detected on two occasions against a panel
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Table 1. Clinical data from patients with renal cortical necrosis (RCN)
Patient
No.
Age Sex Cause of RCN Biopsy
diagnosis
Transfusions
N
Preg-
nancies
Transplants Requir-
ing
dialysisN Outcome
1 25 M Unknown Yes > 10 — 0 — Yes
2 18 F Trauma Yes > 10 0 2 1st rejected in 4 mos.
2nd functioning
No
3 67 M Sepsis No 3—10 — 0 Yes
4 47 M Sepsis No >10 2 0 Yes
5 18 F Abruptio
placenta
Yes > 10 2 1 Hyperacutely rejected Yes
6 40 F Septic abortion Yes > 10 9 1 Hyperacutely rejected Yes
7 18 F Abruptio
placenta
Yes > 10 6 2 1st rejected in 4 mos.
2nd functioning less
than 1 yr
No
8 24 F Abruptio
placenta
No 3—10 1 0 No
9 37 F Obstetrical
accident
No > 10 3 0 Yes
10 55 M Sepsis Yes 3—10 — 0 Yes
11 9 F Sepsis Yes 3—10 0 0 Yes
12 7 M Trauma
(unilateral)
Yes 3—10 — 0 No
13 22 M Sepsis Yes 3—10 — 0 Died
14 34 F Drug sensitivity Yes 3—10 3 0 Yes
Subsequent to the serological evaluation of this patient, she received a transplant which was rejected in one month.
of ten lymphocyte donors by trypan blue dye exclusion
[9]. Detection of antiglomerular basement membrane
(anti-GBM) antibodies was performed by incubating
sera on human renal tissue and staining with fluor-
escent antihuman immunoglobulin sera [10].
Sera were tested for the presence of antibody cap-
able of rendering immune injury and releasing platelet
factor III from platelets according to the method pre-
viously described [11, 12]. Briefly, 0.1 ml of a globulin
fraction prepared from serum was added to 0.1 ml of
platelet-rich plasma collected as previously described
[12] and 0.1 ml of "contact product" prepared as de-
scribed by Nossel [13]. This mixture was incubated for
five minutes at 37°C after which 0.1 ml of 0.025 M
calcium chloride was added to initiate coagulation.
The fibrin end-point was observed and recorded in
seconds. Tests were performed in duplicate and many
were repeated on different days. Results were con-
sidered abnormal if the clotting time was shortened by
ten seconds or more as compared with a simultane-
ously run control. Samples which gave positive results
were titered employing the globulin fraction of normal
serum as diluent. Results were considered positive if
the titer was greater than 1: 8. A titer of 1:8 or less was
considered negative. A positive titer was confirmed if
antiplatelet antibody activity was removed by treat-
ment of the test globulin solution with rabbit anti-
human IgG as described previously [10].
Review of renal allograft survival in patients with
RCN. The posttransplantation courses of patients with
renal failure secondary to RCN were kindly provided
to us through the Organ Transplant Registry of the
American College of Surgeons, National Institutes of
Health, Chicago, Illinois, and through personal com-
munications. The results include all transplants in
patients having had RCN in which the time of trans-
plant failure was established or a follow-up of at least
one year was available. In reporting transplant sur-
vival, graft nonfunction or patient death constituted
failure.
Results
Detection of antibody in sera of patients with RCN.
Shown in Table 1 are the clinical data from 14 patients
with RCN from whom we were able to obtain serum
samples. Evaluation of the sera from these patients is
shown in Table. 2. Three of 11 patients had antibodies
to at least one member of the donor lymphocyte panel.
This 27% incidence of cytotoxic antibody was not
different from that observed in non-RCN renal failure
patients. None of 11 patients tested was found to have
anti-GBM antibodies. Thus, an unusually high inci-
dence of lymphocytotoxic or anti-GBM antibody was
not found in patients with RCN.
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Table 2. Antibody in patients with renal cortical necrosis
Patient
No.
Lympho-
cytotoxic
antibody
Anti-GBM
antibody
Factor III-
releasing anti-
platelet anti-
body
1 — — +
2 — — —
3 — — +
4 — — +
5 + — +
6 + — +
7 + — +
8 — — +
9 — — +
10 — — +
11 NTa NT
12 NT NT +
13 NT NT +
14 — — —
a NT=not tested.
In contrast, 11 of 14 patients were found to have a
serum factor which released platelet factor III. The
release of platelet factor III from platelets was inhi-
bited by treating the globulin fraction with rabbit
antihuman IgG suggesting the active component of the
serum to be immunoglobulin. This 79% incidence of
platelet antibody was significantly higher than that
found among hemodialysis patients with renal failure
due to diseases other than RCN. Thus, among 23 non-
RCN renal failure patients all of whom had had at
least three previous blood transfusions and six having
had more than ten transfusions, we found an incidence
of antiplatelet antibody of 33% (P vs. RCN group <
0.02 by X2 analysis).
Renal allograft survival in patients with RCN. The
results of 37 transplants in 31 patients with renal
failure consequent to RCN were reviewed. These
28 females and 3 males had a mean age of 25 yr at the
time of transplantation. There were 12 live related
donors, 1 live unrelated donor and 24 cadaveric donors.
Only 38% (5/13) of kidney allografts from living re-
lated donors and 35% (8/23) of cadaveric grafts were
functioning six months after transplantation. Overall,
35% (13/37) of all allografts in patients with RCN
functioned less than two days, and 60% (2 1/37) of
grafts not lost during the first two months were rejected
during the first year resulting in a one-year graft sur-
vival of 29.7%.
Discussion
The association of a 79% incidence of antiplatelet
antibody in patients with RCN is a significant new
observation, particularly because of the finding here
and in a previous report [12] of a high incidence of
early transplantation failure in patients with renal
failure consequent to bilateral RCN. Sixty percent of
transplants failed within two months, an early failure
rate which is similar to that reported in patients with
lymphocytotoxic antibodies [5]. Moreover, one-third
of transplants never functioned and 11% were de-
scribed as having been hyperacutely rejected.
It cannot at present be stated with certainty that the
antiplatelet antibody observed in patients with RCN is
responsible for the high incidence of early transplanta-
tion failure in these patients. It is clear, however, that
antiplatelet antibodies are associated with accelerated
or hyperacute rejection. Both cases of hyperacute re-
jection reported by Kissmeyer-Nielsen et al [6] had
antiplatelet antibodies in addition to lymphocytotoxic
antibodies. Moreover, prior sensitization with blood
platelets has been shown to lead to accelerated rejec-
tion of skin allografts in rabbits [15] and man [16] and
renal allografts in dogs [17].
The specificity of the antiplatelet antibody has not
been determined. Although possible, it is unlikely that
the antiplatelet antibody is directed against lympho-
cyte histocompatibility antigens present on platelets,
because only three of nine patients having antiplatelet
activity in the their sera were found to have lymphocyto-
toxic activity (Table 2). In those three patients, of
course, the antiplatelet antibody might be directed
against histocompatibility antigens shared by platelets.
The cause of the appearance of antiplatelet anti-
bodies in RCN is a matter of speculation. Patients with
RCN resulting from obstetrical accidents are fre-
quently multiparous [18] and may have thus been
sensitized [7]. In patients with RCN due to sepsis, cross-
reacting antiplatelet antibodies may arise because of
sensitization to bacterial antigens. Terasaki, Kreisler
and Mickey [19]; Mittal et a! [20]; and Hirata and
Teraskai [211 have shown cross-reactivity of human
transplantation antigens and antigens of streptococci
and lipopolysaccharides from gram-negative bacteria.
Zabriskie et a! have postulated that bacterial immuni-
zation is responsible for hyperresponsiveness to kidney
allografts [22].
The occurrence of platelet antibodies in patients
with RCN resulting from trauma may arise through
sensitization to some degradation products of the
traumatized kidney. Morrison and Baldini have dem-
onstrated that repeated injections of aortic endothe-
hum sensitize dogs to allogeneic blood platelets as
demonstrated by a reduction in survival of allogeneic
but not autologous platelets [23].
The finding of antiplatelet antibody activity in one-
third of "control" patients with non-RCN renal
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failure raises the question of the reliability of the pro-
cedure for determining antiplatelet antibody in
patients with renal failure. In such patients anti-
platelet antibodies may arise as a result of sensitization
to histocompatibility and platelet antigens by prior
transfusions and pregnancies. All of our "control"
patients with renal failure had had at least three prior
transfusions (one-fourth having had more than ten)
and one-third had been pregnant. Moreover, all the
factor Ill-releasing activity determinations were per-
formed by one of us (S. K.) without knowledge of the
clinical status of the patient, thereby minimizing the
internal variation of the procedure. Nevertheless, con-
tinued study of renal failure patients is needed to help
understand the clinical significance of the considerable
incidence of platelet antibody in non-RCN renal
failure patients.
The role of antiplatelet antibody in precipitating
forms of RCN other than allograft RCN is difficult to
establish. Experimentally, RCN has been produced in
rabbits by administering antigen to specifically sensi-
tized animals, or soluble antigen-antibody complexes
to unsensitized animals [24]. It is postulated that these
antigen-antibody complexes activate the complement
pathway and lead to fibrin deposition in the kidneys
[24]. The development of an antiplatelet antibody in a
previously healthy individual might result in RCN by
similar pathogenetic mechanisms. However, only by
prospective testing of sera from individuals who de-
velop antiplatelet antibodies and subsequently develop
RCN can the pathogenetic role of antiplatelet anti-
body be determined. Further clarification of this issue
is needed to aid understanding of the pathogenesis of
RCN and to allow more careful selection of patients
with RCN for transplantation.
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